The next frontier in gene therapy may not be rewriting DNA at all. Instead, it’s editing RNA: precise, reversible, and flexible.
RNA editing is rapidly gaining prominence. Unlike DNA editing, it avoids the ethical and safety concerns of permanent genome modification. More importantly, RNA edits are reversible, making them a powerful and precise approach to gene therapy.
One of the most widespread RNA modifications is A-to-I editing, where ADAR enzymes (Adenosine Deaminases Acting on RNA) convert adenosine (A) to inosine (I) in double-stranded RNA. Because inosine is interpreted as guanosine (G), these edits can reshape RNA stability, splicing, and translation. This is fundamentally changing how cells read and use genetic information.
Engineered ADAR systems are now being paired with guide RNAs (gRNAs) to target specific sites, opening the door to RNA-editing therapies with higher precision than DNA-based tools like CRISPR-Cas9.
To support this growing field, SignalChem Biotech is proud to introduce its new recombinant human ADAR proteins: ADAR1 (p150), ADAR1 (p110), and ADAR2L (ADARB1) now offered with innovative in-house developed activity assays. These tools enable researchers to:
- Perform in vitro deamination assays to study RNA editing mechanisms.
- Identify RNA targets of ADAR activity.
- Screen modulators that influence ADAR function.
As ADAR biology moves from discovery to therapeutic applications, having reliable reagents and assays is key. We’re excited to help scientists explore this frontier of RNA editing with confidence.
Learn more about our ADAR products here: https://www.sinobiological.com/category/ads/adar-enzymes
